Better Therapeutics Announces Publication of Cost-Effectiveness Analysis Demonstrating AspyreRx is More Effective and Less Costly than Standard of Care Alone
- AspyreRx plus standard of care was estimated to be superior to SoC alone, providing more life years and improvements in quality of life at a lower cost
- AspyreRx was associated with gains in quality-adjusted life years (QALYs) and cost savings of $7,343 per patient over the lifetime horizon
- The study supports the potential efficacy and economic viability of digital therapeutics, recognizing the cost-effectiveness of integrating digital therapeutics into mainstream clinical practice
- None.
Insights
The economic analysis of AspyreRx, a prescription digital therapeutic for type 2 diabetes, presents a significant development in the healthcare industry. The study's findings that AspyreRx plus standard of care (SoC) is more cost-effective than SoC alone, with a reduction in costs and improvement in quality-adjusted life years (QALYs), suggest a potential shift in diabetes management strategies. From a health economics perspective, the dominance of AspyreRx in this study—indicated by both cost savings and health benefits—could influence healthcare payers' decisions on coverage and reimbursement policies. The incremental net monetary benefit (INMB) figures at various willingness-to-pay thresholds further reinforce the economic argument for integrating AspyreRx into treatment regimens.
Understanding the economic burden of diabetes, which includes direct healthcare costs and indirect costs such as lost productivity, is crucial for evaluating the broader impact of AspyreRx's adoption. The reported savings, primarily driven by a reduction in drug costs and adverse event costs, could alleviate some of the financial strain on healthcare systems. It is important to note, however, that these findings are based on a model and actual real-world outcomes may vary. Long-term studies and real-world evidence will be essential to validate these modeled cost-effectiveness outcomes.
The reported clinical superiority of AspyreRx in conjunction with standard of care over SoC alone is an important consideration for clinicians and patients managing type 2 diabetes. The use of personalized cognitive behavioral therapy delivered digitally could represent a paradigm shift in treating chronic conditions like diabetes, which traditionally rely heavily on pharmacotherapy. The study's emphasis on clinically meaningful and durable reductions in hemoglobin A1c indicates that AspyreRx has the potential to impact long-term health outcomes positively.
However, while the study's publication in a peer-reviewed journal adds to its credibility, it is essential to scrutinize the methodology and the assumptions underlying the model. The healthcare community should consider the generalizability of these findings to diverse patient populations and healthcare settings. Additionally, the adoption of digital therapeutics hinges not only on clinical and economic outcomes but also on patient engagement, adherence and integration into existing healthcare workflows.
The publication of health economic data for Better Therapeutics Inc.'s AspyreRx could have implications for investor perceptions and the company's market position. As the prevalence of type 2 diabetes increases, along with its associated economic burden, the market demand for innovative and cost-effective treatments is likely to grow. Better Therapeutics' focus on prescription digital therapeutics (PDTs) places it at the intersection of technology and healthcare, a burgeoning sector with significant investment potential.
Investors will be interested in the scalability of AspyreRx and its potential market penetration, given the study's positive implications for cost savings and improved patient outcomes. The digital therapeutic's ability to deliver personalized cognitive behavioral therapy could set it apart from traditional diabetes management tools and medications. While this publication is a positive signal, investors should monitor the adoption rate of AspyreRx and await further validation from real-world use before drawing conclusions about its long-term market impact.
Over a lifetime horizon AspyreRx plus standard of care (SoC) was estimated to be superior to SoC alone providing more life years and improvements in quality of life at a lower cost
Study suggests that using AspyreRx can empower patients to better manage their diabetes, with the potential to reduce long-term complications
The study's authors conclude that, from a healthcare payer perspective, AspyreRx plus standard of care (SoC) was estimated to be both economically and clinically superior to SoC alone over the lifetime horizon. This suggests that the use of AspyreRx can empower patients to better manage their diabetes with the potential for lifelong advantages.
As the prevalence of diabetes and the associated economic burden continues to escalate, there is a pressing need for a novel treatment approach. According to the American Diabetes Association, the estimated national cost of diabetes in 2022 was
AspyreRx delivers a novel form of personalized cognitive behavioral therapy, backed by robust data demonstrating clinically meaningful and durable hemoglobin A1c reductions in patients with T2D. This latest study modeled the cost-effectiveness of AspyreRx plus SoC versus SoC alone in T2D over a lifetime horizon. The analysis followed the modeling precedent established by the Institute for Clinical and Economic Review (ICER) for the appraisals of T2D medications.
From a healthcare payer perspective, AspyreRx plus SoC versus SoC alone was dominant because AspyreRx was associated both with gains in quality-adjusted life years (QALYs) and cost savings of
“This study adds to the growing body of evidence supporting the potential efficacy and economic viability of digital therapeutics,” said Niall Davison, Senior Scientific Lead at Maple Health Group. “In an evolving landscape where technology converges with healthcare, recognizing the cost-effectiveness of integrating digital therapeutics into mainstream clinical practice is crucial in driving sustainable solutions that can benefit both patients and the overall healthcare system.”
"Despite many new drugs having been developed over the past decades to treat T2D, the prevalence and associated costs of this condition has continued to increase to unprecedented levels," said Frank Karbe, President and CEO at Better Therapeutics. "The publication of this data, demonstrating that adding AspyreRx to standard of care has the potential to be more effective and less costly than standard of care alone, exemplifies our vision to make societies healthier and meaningfully reduce healthcare costs.”
About Better Therapeutics
Better Therapeutics is a prescription digital therapeutics company developing a novel form of cognitive behavioral therapy to address underlying factors that sustain or worsen cardiometabolic diseases. The Company has developed a proprietary platform for the development of FDA-regulated, software-based solutions for T2D, heart disease and other conditions. The CBT delivered by Better Therapeutics’ PDTs is designed to enable changes in neural pathways of the brain so lasting changes in behavior become possible. Addressing the underlying causes of these diseases has the potential to dramatically improve patient health while lowering healthcare costs. Better Therapeutics’ clinically validated mobile applications are intended to be prescribed by physicians and reimbursed like traditional medicines.
For more information visit: bettertx.com
About AspyreRx
AspyreRx (formerly BT-001) was granted marketing authorization by the FDA in July 2023 as the first prescription-only digital therapeutic to treat adults with type 2 diabetes (T2D). AspyreRx is backed by robust data demonstrating clinically meaningful and sustained reduction in A1c as well as improvements in other markers of cardiometabolic health when used up to 180 days. Using proven techniques that target the underlying psychological, behavioral, and cognitive factors that sustain or worsen T2D, AspyreRx is a self-paced, engaging experience that patients can access from their smartphone. It is prescribed by a healthcare provider in 90-day increments, with proprietary CBT delivered digitally in a weekly step-by-step process. Through interactive therapy lessons, skill-building modules, weekly goal setting and tracking, patients connect changes in behavior to improvements in blood sugar and other biometrics. Each step in the experience builds on the prior to enable and reinforce cognitive restructuring, building the emotional resilience and acceptance needed to make enduring changes.
Indication for Use
AspyreRx is a prescription-only digital therapeutic device intended to provide cognitive behavioral therapy to patients 18 years or older with type 2 diabetes. The device targets behavior to aid in the management of type 2 diabetes in patients who are under the care of a healthcare provider. AspyreRx provides cognitive behavioral therapy as a treatment that should be used adjunctively with standard of care.
Forward Looking Statements
Certain statements made in this press release are “forward-looking statements” within the meaning of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are typically identified by words such as “plan,” “believe,” “expect,” “anticipate,” “intend,” “outlook,” “estimate,” “forecast,” “project,” “continue,” “could,” “may,” “might,” “possible,” “potential,” “predict,” “should,” “would” and other similar words and expressions, but the absence of these words does not mean that a statement is not forward-looking. The forward-looking statements in this press release include, but are not limited to, statements regarding Better Therapeutics’ expectations related to the efficacy and potential benefits of PDTs, including AspyreRx and CBT, and their potential treatment applications and their ability to improve clinical outcomes, expectations regarding the amendment to the Hercules debt facility and the outcome and success of cost saving initiatives, including salary reductions, and operational plans and their impact on Better Therapeutics’ financial position and cash runway, and expectations regarding the commercial traction of AspyreRx and partnering discussions, among others. These forward-looking statements are based on the current expectations of the management of Better Therapeutics and are inherently subject to uncertainties and changes in circumstances and their potential effects and speak only as of the date of such statement. There can be no assurance that future developments will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements including: risks related to Better Therapeutics’ business, such as the willingness of the FDA to authorize PDTs, for commercial distribution and insurance companies to reimburse their use, market acceptance of PDTs, including AspyreRx, the risk that the results of previously conducted studies will not be interpreted favorably by the FDA or repeated or observed in ongoing or future studies involving Better Therapeutics’ product candidates and other risks and uncertainties included under the header “Risk Factors” in Better Therapeutics’ quarterly report on Form-10-Q for the fiscal quarter ended September 30, 2023 filed with the Securities and Exchange Commission (“SEC”) on November 09, 2023, and those that are included in any of the Company’s subsequent filings with the SEC.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240116963541/en/
Investor Relations and Media Enquiries:
Emma Williams
info@bettertx.com
Source: Better Therapeutics Inc.
FAQ
What is the ticker symbol for Better Therapeutics Inc.?
What is the study titled that has been published for AspyreRx?
What were the cost savings per patient associated with AspyreRx over the lifetime horizon?
What were the primary drivers of savings in the study?
What are the estimated national costs of diabetes in 2022?
